1. Utility of Left Ventricular Ejection Fraction Measurements Before the Administration of Doxorubicin-Based Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma 
Deborah L. Enns, PhD, Margaret T. Mandelson, PhD, David M. Aboulafia, MD 
Mayo Clinic Proceedings: Innovations, Quality & Outcomes  
Volume 2, Issue 3, Pages (September 2018)
DOI: /j.mayocpiqo
Copyright © 2018 Mayo Foundation for Medical Education and Research Terms and Conditions

2. Figure 1
Left ventricular ejection fraction status and chemotherapy treatments administered to patients with diffuse large B-cell lymphoma. DOX = doxorubicin-based chemotherapy; HIV = human immunodeficiency virus; LVEF = left ventricular ejection fraction.
Mayo Clinic Proceedings: Innovations, Quality & Outcomes  2018 2, DOI: ( /j.mayocpiqo )
Copyright © 2018 Mayo Foundation for Medical Education and Research Terms and Conditions

3. Figure 2
Left ventricular ejection fraction status, incidence of cardiac disease at the time of diagnosis, and subsequent treatments administered to patients with diffuse large B-cell lymphoma. DOX = doxorubicin-based chemotherapy; LVEF = left ventricular ejection fraction.
Mayo Clinic Proceedings: Innovations, Quality & Outcomes  2018 2, DOI: ( /j.mayocpiqo )
Copyright © 2018 Mayo Foundation for Medical Education and Research Terms and Conditions